Overview
Postobstructive pneumonia (POPV) arises from chronic obstruction of a major airway, leading to bronchial collateral vessel proliferation and pulmonary arterial abnormalities, characterized by remodeling and potential vasoconstriction mediated by factors like endothelin-1. 12Diagnosis
Elevated endothelin-1 (ET-1) immunoreactivity observed in pulmonary arteries and new bronchial vessels via immunohistochemistry. 2
No significant difference in plasma ET-1 levels between obstructed and control pulmonary arteries, suggesting localized rather than systemic ET-1 dysregulation. 2
Morphometric analysis showing reduced vessel diameters without changes in muscle thickness indicative of structural changes. 1Management
No specific drug doses or first-line treatments explicitly mentioned in the abstracts for POPV management.
Monitoring and addressing pulmonary vascular reactivity, potentially through agents affecting ET-1 pathways, may be considered based on observed vasoconstriction. 12Special Populations
No specific data provided regarding pregnancy, pediatrics, elderly, or comorbidities in the given abstracts. 12Key Recommendations
Evaluate pulmonary vascular reactivity to endothelin-1 in patients with suspected POPV to guide targeted therapy. (Evidence: Moderate) 12
Consider localized ET-1 pathway modulation in management strategies given increased ET-1 immunoreactivity in affected vessels. (Evidence: Weak) 2
Conduct morphometric assessments of pulmonary vessels to identify structural changes indicative of POPV progression. (Evidence: Moderate) 1References
1 Shi W, Cernacek P, Hu F, Michel RP. Endothelin reactivity and receptor profile of pulmonary vessels in postobstructive pulmonary vasculopathy. The American journal of physiology 1997. link
2 Giaid A, Stewart DJ, Michel RP. Endothelin-1-like immunoreactivity in postobstructive pulmonary vasculopathy. Journal of vascular research 1993. link